|
시장보고서
상품코드
1812416
스타틴 시장 : 제품 유형별, 약물 종류별, 적응증별, 스타틴 유형별, 제형별, 농도별, 판매 채널별, 연령층별, 성별, 유통 채널별, 지역별Statins Market, By Product Type, By Drug Class, By Indication Prevention of Myocardial, By Type of Statin, By Formulation, By Strength, By Sales Channel, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
스타틴 시장은 2025년에 172억 5,000만 달러로 추정되며, 2032년에는 249억 6,000만 달러에 달할 전망이며, 2025년부터 2032년까지 CAGR로 5.42%의 성장이 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 172억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2020-2024년 |
| 예측 기간 : 2025-2032년 CAGR | 5.42% | 2032년 가치 예측 | 249억 6,000만 달러 |
스타틴 세계 시장은 심혈관 치료에서 가장 중요한 의약품 분야 중 하나이며, 전 세계 심장병 치료와 예방에 혁명을 가져온 콜레스테롤 저하제를 포괄하는 시장입니다. 과학적으로 HMG-CoA 환원효소 억제제로 알려진 스타틴은 간에서 콜레스테롤 합성을 담당하는 효소를 억제하여 저밀도 지단백(LDL) 콜레스테롤 수치를 효과적으로 낮추고 심혈관 위험 요인을 최소화하는 역할을 합니다. 이 시장은 고콜레스테롤혈증 유병률 증가, 심혈관질환에 대한 인식 증가, 전 세계 노인 인구의 증가 등을 배경으로 크게 성장하고 있습니다.
이 시장에는 아토르바스타틴, 심바스타틴, 로수바스타틴, 프라바스타틴, 로바스타틴 등 다양한 스타틴 제제가 있으며, 다양한 환자의 니즈를 충족시키기 위해 다양한 제형과 강도로 판매되고 있습니다. 심혈관계 질환은 여전히 전 세계 사망의 주요 원인으로, 스타틴은 주요 심혈관계 부작용 감소에 대한 광범위한 임상적 근거를 바탕으로 일차 및 이차 예방 전략의 핵심 약물로 자리매김하고 있습니다. 시장 상황은 브랜드 의약품과 제네릭 의약품이 모두 존재하는 것이 특징이며, 특허 만료는 가격 역학에 큰 영향을 미치는 동시에 전 세계 다양한 경제 부문의 환자 접근성을 향상시키는 동시에 특허 만료로 인한 가격 역학에 큰 영향을 미치고 있습니다.
시장 역학
스타틴 세계 시장은 몇 가지 강력한 촉진요인에 의해 뒷받침되고 있습니다. 특히 선진국과 개발도상국 모두에서 좌식 생활습관, 건강에 해로운 식습관, 비만율이 지속적으로 증가함에 따라 심혈관질환과 고콜레스테롤혈증 유병률의 증가가 주요 성장 촉매제가 되고 있습니다. 심혈관계 합병증 위험이 높은 고령 인구의 증가는 콜레스테롤 저하 요법에 대한 지속적인 수요를 창출하는 한편, 의료비 지출 증가와 보험 적용 범위 확대는 시장 접근성을 높이고 있습니다. 예방의학에 대한 인식이 높아지고 정기적인 콜레스테롤 검진 프로그램은 조기 진단과 치료 시작을 유도하여 스타틴 치료를 필요로 하는 환자군을 더욱 확대시키고 있습니다.
그러나 주요 브랜드 스타틴의 특허만료에 따른 제네릭 의약품의 보급으로 가격경쟁이 심화되고 제약사의 이익률이 하락하는 등 시장은 큰 억제요인에 직면해 있습니다. 근육 관련 증상, 간 효소 상승, 잠재적 당뇨병 위험 등 스타틴과 관련된 부작용에 대한 안전성 우려는 일부 의사와 환자들에게 주저하게 만들고 처방 패턴에 영향을 미치고 있습니다. 또한, PCSK9 억제제 및 새로운 지질 개선제를 포함한 대체 콜레스테롤 저하 요법의 등장은 기존 스타틴 치료에 대한 경쟁적 도전에 직면하고 있습니다. 새로운 제형과 적응증에 대한 복잡한 규제와 까다로운 승인 절차는 시장 진입과 기술 혁신의 장벽이 되고 있습니다. 하지만 부작용을 줄이면서 효능을 높이는 병용요법 개발, 헬스케어 인프라가 발달한 신흥국 시장 진출, 염증억제, 신경보호 등 콜레스테롤 관리 외의 새로운 스타틴 응용 모색 등을 통해 치료 영역과 시장의 가능성을 크게 확대할 수 있는 가능성이 큽니다.
본 조사의 주요 특징
- 세계의 스타틴 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 동안 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 본 보고서에서는 세계 스타틴 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 파라미터를 기준으로 정리하여 수록하였습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 스타틴 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 스타틴 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 분석
- 인수합병 시나리오
- 업계 동향
제4장 세계의 스타틴 시장, 제품 유형별, 2020-2032년
- 제네릭 의약품
- 브랜드 의약품
제5장 세계의 스타틴 시장, 약물 종류별, 2020-2032년
- 아토르바스타틴
- 플루바스타틴
- 로바스타틴
- 프라바스타틴
- 로수바스타틴
- 심바스타틴
- 피타바스타틴
제6장 세계의 스타틴 시장, 적응증별, 2020-2032년
- 심근경색 예방
- 뇌졸중 예방
- 2형 당뇨병 관련 심근경색 및 뇌졸중 예방
- 관상동맥질환 위험 감소
- 원발성 고지혈증 치료
- 혼합형 이상지질혈증 치료
- 고중성지방혈증 및 원발성 이상 β리포단백질혈증
- 동형접합 가족성 고콜레스테롤혈증(HoFH) 치료
- 이형접합 가족성 고콜레스테롤혈증(HeFH) 치료(소아)
제7장 세계의 스타틴 시장, 스타틴 유형별, 2020-2032년
- 천연 스타틴
- 합성 스타틴
제8장 세계의 스타틴 시장, 제형별, 2020-2032년
- 정제
- 캡슐
제9장 세계의 스타틴 시장, 농도별, 2020-2032년
- 10mg
- 20mg
- 40mg
- 80mg
제10장 세계의 스타틴 시장, 판매 채널별, 2020-2032년
- 처방
- OTC
제11장 세계의 스타틴 시장, 연령층별, 2020-2032년
- 소아
- 성인
- 노인
제12장 세계의 스타틴 시장, 성별, 2020-2032년
- 남성
- 여성
제13장 세계의 스타틴 시장, 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제14장 세계의 스타틴 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제15장 경쟁 구도
- Pfizer Inc.
- AstraZeneca
- Merck & Co.
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players
제16장 애널리스트의 추천사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제17장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Statins Market is estimated to be valued at USD 17.25 Bn in 2025 and is expected to reach USD 24.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.42% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 17.25 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.42% | 2032 Value Projection: | USD 24.96 Bn |
The global statins market represents one of the most significant pharmaceutical segments in cardiovascular therapeutics, encompassing cholesterol-lowering medications that have revolutionized the treatment and prevention of heart disease worldwide. Statins, scientifically known as HMG-CoA reductase inhibitors, function by blocking the enzyme responsible for cholesterol synthesis in the liver, effectively reducing low-density lipoprotein (LDL) cholesterol levels and minimizing cardiovascular risk factors. This market has experienced substantial growth driven by the increasing prevalence of hypercholesterolemia, rising awareness of cardiovascular diseases, and expanding geriatric population globally.
The market encompasses various statin formulations including atorvastatin, simvastatin, rosuvastatin, pravastatin, and lovastatin, available in multiple dosage forms and strengths to cater to diverse patient needs. With cardiovascular diseases remaining the leading cause of mortality worldwide, statins have become cornerstone medications in both primary and secondary prevention strategies, supported by extensive clinical evidence demonstrating their efficacy in reducing major adverse cardiovascular events. The market landscape is characterized by the presence of both branded and generic formulations, with patent expirations having significantly impacted pricing dynamics while simultaneously improving accessibility for patients across different economic segments globally.
Market Dynamics
The global statins market is propelled by several compelling drivers, with the escalating prevalence of cardiovascular diseases and hypercholesterolemia serving as primary growth catalysts, particularly as sedentary lifestyles, unhealthy dietary patterns, and obesity rates continue to rise across developed and developing nations. The expanding geriatric population, who are inherently at higher risk for cardiovascular complications, creates sustained demand for cholesterol-lowering therapies, while increasing healthcare expenditure and improved insurance coverage enhance market accessibility. Growing awareness about preventive healthcare measures and routine cholesterol screening programs have led to earlier diagnosis and treatment initiation, further expanding the patient pool requiring statin therapy.
However, the market faces significant restraints including the widespread availability of generic alternatives following patent expirations of major branded statins, which has intensified price competition and compressed profit margins for pharmaceutical companies. Safety concerns related to statin-associated adverse effects such as muscle-related symptoms, liver enzyme elevations, and potential diabetes risk have created hesitancy among some physicians and patients, impacting prescription patterns. Additionally, the emergence of alternative cholesterol-lowering therapies, including PCSK9 inhibitors and newer lipid-modifying agents, poses competitive challenges to traditional statin therapy. Regulatory complexities and stringent approval processes for new formulations or indications create barriers to market entry and innovation. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance efficacy while potentially reducing side effects, expansion into emerging markets with growing healthcare infrastructure, and the exploration of novel statin applications beyond cholesterol management, including potential benefits in inflammation reduction and neuroprotection, which could significantly broaden the therapeutic scope and market potential.
Key Features of the Study
- This report provides in-depth analysis of the global statins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global statins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Merck & Co, Novartis AG, Medicure Inc., Teva Pharmaceutical, Mylan NV, Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Laboratories, Kowa Pharmaceuticals, and other prominent players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global statins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global statins market.
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic Drugs
- Branded Drugs
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Atorvastatin
- Fluvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Pitavastatin
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Prevention of Myocardial Infarction
- Stroke Prevention
- Type 2 Diabetes-related MI and Stroke Prevention
- Coronary Heart Disease Risk Reduction
- Primary Hyperlipidemia Treatment
- Mixed Dyslipidemia Treatment
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Type Of Statin Insights (Revenue, USD Bn, 2020 - 2032)
- Natural Statins
- Synthetic Statins
- Formulation Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets
- Capsules
- Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 10 mg
- 20 mg
- 40 mg
- 80 mg
- Sales Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription
- Over-the-Counter
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- AstraZeneca
- Merck & Co
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Statins Market, By Product Type
- Global Statins Market, By Drug Class
- Global Statins Market, By Indication
- Global Statins Market, By Type of Statin
- Global Statins Market, By Formulation
- Global Statins Market, By Strength
- Global Statins Market, By Sales Channel
- Global Statins Market, By Age Group
- Global Statins Market, By Gender
- Global Statins Market, By Distribution Channel
- Global Statins Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Statins Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Statins Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Atorvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lovastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pravastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rosuvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Simvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pitavastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Statins Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prevention of Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Type 2 Diabetes-related MI and Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Coronary Heart Disease Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Hyperlipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Dyslipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Statins Market, By Type of Statin, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Natural Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Synthetic Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Statins Market, By Formulation, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Statins Market, By Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 10 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 40 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 80 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Statins Market, By Sales Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Statins Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Statins Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Statins Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
14. Global Statins Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
15. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Medicure Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
16. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
17. References and Research Methodology
- References
- Research Methodology
- About us
